Market Place
Sourcing Support
Theratechnologies Reveals Trial Design For Ibalizumab People with HIV
17 Oct 2024 //
GLOBENEWSWIRE
Theratechnologies Highlights Impact Of EVAF On CVD Risk In HIV
17 Oct 2024 //
GLOBENEWSWIRE
Theratechnologies Reports Strong Q3 2024 Financial Results
10 Oct 2024 //
GLOBENEWSWIRE
Theratechnologies To Present HIV Treatment Data At IDWeek
09 Oct 2024 //
GLOBENEWSWIRE
Theratechnologies To Announce Third Quarter 2024 Results
26 Sep 2024 //
GLOBENEWSWIRE
Theratechnologies Warns Of Egrifta Supply Disruption After Plant Shutdown
18 Sep 2024 //
FIERCE PHARMA
Theratechnologies Announces Risk of EGRIFTA SV® Supply Disruption
17 Sep 2024 //
GLOBENEWSWIRE
Theratechnologies to Present at Upcoming Investor Conferences
09 Sep 2024 //
GLOBENEWSWIRE
Theratechnologies Reports Q2 2024 Results With Positive Net Income
10 Jul 2024 //
GLOBENEWSWIRE
Theratechnologies To Announce Q2 2024 Financial Results
26 Jun 2024 //
GLOBENEWSWIRE
Theratechnologies Sudocetaxel Data: Efficacy Safety In Solids At Asco24
23 May 2024 //
GLOBENEWSWIRE
Theratechnologies Reports on its Annual Meeting of Shareholders
09 May 2024 //
GLOBENEWSWIRE
Theratechnologies: TH1902 Long-Term Solid Tumor Data At ASCO 2024
02 May 2024 //
GLOBENEWSWIRE
Theratechnologies Mails Proxy Circular For Shareholder Meeting
15 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies At Bloom Burton Healthcare Investor Conf 2024
11 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies Reports Q1 2024 Financials and Business Update
10 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies Preclinical Data Presentation at AACR 2024
08 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies Appoints Elina Tea to its Board of Directors
05 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies to Announce First Quarter 2024 Financial Results
03 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies to Present Preclinical Data at AACR
28 Mar 2024 //
GLOBENEWSWIRE
Theratechnologies Announces Update on its Preclinical Oncology Research Program
22 Mar 2024 //
GLOBENEWSWIRE
Theratech Initiates Ph 1 Trial of Sudocetaxel Zendusortide in Ovarian Cancer
21 Mar 2024 //
GLOBENEWSWIRE
Theratechnologies Appoints Jordan Zwick to its Board of Directors
21 Mar 2024 //
GLOBENEWSWIRE
Theratechnologies Announces the Resignation of Mr. Alain Trudeau
29 Feb 2024 //
GLOBENEWSWIRE
Theratechnologies hit with FDA refusal to file letter for HIV drug
27 Feb 2024 //
ENDPTS
Theratechnologies Reports Financial Results for Q4 and Full Year of Fiscal 2023
21 Feb 2024 //
GLOBENEWSWIRE
Theratechnologies Announces Publication in Frontiers in Immunology
20 Feb 2024 //
GLOBENEWSWIRE
Theratechnologies Completes Enrollment in Ph 1 Trial of Sudocetaxel Zendusortide
15 Feb 2024 //
GLOBENEWSWIRE
Theratechnologies to Announce Fourth Quarter & Full Year 2023 Financial Results
06 Feb 2024 //
GLOBENEWSWIRE
FDA declines to approve new form of HIV-associated lipodystrophy drug
25 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Receives Update from FDA on Tesamorelin F8 sBLA
23 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Submits sBLA for Trogarzo IM Method of Administration to FDA
02 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Announces FDA Approval of Trogarzo 90-Second IV Loading Dose
13 Dec 2023 //
GLOBENEWSWIRE
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
24 Nov 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Closing of US$25M Public Offering of Common Shares
31 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Pricing of US$25M Public Offering of Common Shares
26 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Proposed Public Offering of Common Shares
25 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Operational Update
24 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Ibalizumab Shows Cost-Effectiveness as an Addition to Routine
19 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Finalization of Amendments
16 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Study
13 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces VAT
13 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Dosing of First Patient in Trial of Sudocetaxel Zendusortide
12 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin
04 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Reports Financial Results for the Third Quarter
26 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
25 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Agreement in Principle with Marathon
25 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies to Present at the Cantor Fitzgerald Global Conference 2023
20 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies to Announce Third Quarter 2023 Financial Results
18 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies to Present at Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
05 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies All U.S. Onco Sites for Ph1 Trial of Sudocetaxel Zendusortide
30 Aug 2023 //
GLOBENEWSWIRE
Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite
21 Aug 2023 //
PR NEWSWIRE
Theratechnologies Completes 1-for-4 Reverse Stock Split
31 Jul 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Amendments to its Term Loan Facility
28 Jul 2023 //
GLOBENEWSWIRE
Theratechnologies Announces the Resignation of Directors, Mr. Gary Littlejohn
21 Jul 2023 //
GLOBENEWSWIRE
Theratechnologies Announces 1-for-4 Reverse Stock Split
20 Jul 2023 //
GLOBENEWSWIRE
Theratechnologies to lay off R&D staff to offset sales setback
12 Jul 2023 //
FIERCE BIOTECH
Theratechnologies Reports Q2 2023 Financial Results and Business Updates
12 Jul 2023 //
GLOBENEWSWIRE
